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Background: This study is the first to examine the understandings that participants have of the consent process
in a pharmacogenetic trial of anti-depressant medication.
Methods: This was a qualitative cross sectional study. There were 76 participants residing in London, Mannheim,
Arhuus and Poznan.
Results: Only one quarter of participants (none in Poznan) could articulate the concept of pharmacogenetics.
Heritability and testing medication were also given as the purpose of the trial. Most participants had not
appreciated harms that could derive from the trial. Even when shown the consent sheet, participants were
confused about DNA profiling. There was evidence that participants appreciated weekly contact with researchers.
Most said they would participate in a trial again but would like choice over the intervention they were assigned to.
Conclusion: Participants in this study showed a poor level of informed consent. Although this is not the first time
this argument has been made, it is in the case of a pharmacogenetic trial. Further work should investigate the
associations between extraneous factors such as information and social support on beneficial or untoward
outcomes of antidepressant treatment.Background
We have come to rely on clinical trial data to provide
the evidence base for treatments. But what do partici-
pants think about being involved in trials and could their
perceptions have an affect on outcomes? In this study,
we examine the perceptions of people with a diagnosis
of depression who took part in a pharmacogenetic trial
of anti-depressant medication.
The views of participants in trials have received some
attention in general medicine. Ellis [1] carried out a sys-
tematic review of both doctors’ and patients’ attitudes to
Randomised Controlled Trials in the field of cancer focus-
ing in particular on randomisation and informed consent.
Ellis argues that randomisation is a hurdle to recruitment
as potential participants want choice over treatment and* Correspondence: diana.rose@kcl.ac.uk
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reproduction in any medium, provided the orthat comprehension of information is often low. The
McArther group [2,3] argue that participants in trials
suffer from a ‘therapeutic misconception’ when they fail
to distinguish clinical care from research and believe
that participation in research comprises individualised
treatment.
It is often argued that psychiatric patients have impaired
decision making capacity which poses special hurdles in
obtaining informed consent. This is particularly so in neu-
rodegenerative conditions of the brain such as Alzheimer’s
disease and there have been recent calls for clarification
on the issues of proxy and surrogate consent [4]. However,
it has also been argued that other psychiatric diagnoses
can lead to impaired decision making, including schizo-
phrenia and depression. Nevertheless, in a series of stud-
ies, Roberts interviewed people with the condition most
associated with impaired decision making, schizophrenia,
and found no difference between their comprehension of
the procedure of the trial and that of people without ad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[5]). We consider impaired capacity in depression in the
Discussion section of this paper.
As far as we can ascertain, there have been no empirical
studies of the perceptions of participants in pharmaco-
genetic studies in psychiatry although there have been
conceptual reviews [6-8]. Issues of informed consent in
mental health studies are unlikely to differ between
pharmacogenetic and other studies as there remains a
focus on capacity and vulnerable individuals. Informed
consent entails understanding the purpose of a study and
achieving it in pharmacogenetic studies may be more diffi-
cult as the concept is not easy to grasp. Indeed it is not
easy for members of the general public or some policy
makers to grasp [9].
For pharmacogenetics studies there is also another im-
portant consideration for participants and that is tissue
banking and DNA profiling. Two conceptual reviews [6,7]
discuss issues such as the retention of samples for further
research, the problem of whether or not results should
be disclosed to participants, the interests of families and
discrimination. In the present study, samples of blood
were drawn, were anonymised and participants assured
of confidentiality. However, they were aware that their
blood samples would be used for research and stored
centrally in the main study site.Objectives
1. To assess trial participants’ understanding of
information during the informed consent process of
GENDEP.
2. T o investigate the correspondence between the
aims of scientists and the understanding of
participants in GENDEP.Context of the study
The study reported here was part of a wider investigation.
GENDEP is a multi-disciplinary programme of research in-
cluding a human study of the pharmacogenetics of anti-
depressant medication. Other parts of the study included
in vitro work and work on animal models. The human part
was an open-label partially randomised trial. It took place
in eight European countries [10] (for general background to
GENDEP see: http://gendep.iop.kcl.ac.uk/background.php).
The funders of GENDEP, with strong support from the
main study, required a component of the research to be
its Ethical, Legal and Social Implications (ELSI). The
participants’ perceptions work was carried out within the
Service User Research Enterprise (SURE) who undertook
focus groups with service users as well as the study
reported here. Essentially, the ELSI research ‘piggy backed’
on the main human study.The GENDEP main human study took place in nine sites
(2 in Germany) and the ELSI sites were chosen to be repre-
sentative of these. They were: London UK; Mannheim
Germany; Aarhus Denmark and Poznan Poland.
Method
Study design
This was a cross-sectional qualitative study.
Study sites
The study sites were London UK, Aarhus, Denmark,
Mannheim, Germany and Poznan, Poland. There were 9
study sites in the main study and the ELSI study sites
were chosen to be representative of these, including the
inclusion of a former Soviet Bloc country and new en-
trant to the EU (Poland).
Health service configuration differed slightly amongst
the sites chosen:
London: limited availability of psychological therapy in
public health services.
Mannheim: no additional treatment available apart
from medication except in private practice.
Aarhus: Availability of CBT for all people diagnosed
with depression although long waiting lists.
Poznan: Limited pharmacopeia available outside the
trial and no psychological treatments available in the
health services. Most health services must be paid for.
In all countries there was some charge for medication
although the amount varied. The drugs for the GENDEP
trial were provided free of charge by a pharmaceutical
company.
Study population and sampling framework
The sampling framework was all participants who had
taken part in GENDEP in the four ELSI sites at the point
of receipt of ethical approval. All eligible participants
were sent a letter from the main study researchers and
the letters gave contact details of the interviewer for
those interested in taking part in the ELSI interviews.
The ELSI researcher then made an appointment for
interview at a venue of the participant’s choosing.
Study period
Data were collected in London between January and
August 2006; in Aarhus between January 2007 and August
2007; in Mannheim between July 2006 and January 2007;
and in Poznan in March and April 2007. All transcrip-
tions were complete and checked at the end of 2007.
The London data was analysed in London in 2008, the
Mannheim and Poznan data in Berlin during 2008 and
2009 and the Danish data was analysed in London in
2009.
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Data collection was by semi-structured, individual, face-
to-face interviews. The interviews were audiotaped,
transcribed verbatim and translated into English. One
researcher was bi-lingual and carried out interviews in
both English and German in London and Mannheim.
The same researcher worked in Poznan with an inter-
preter. In Aarhus a specific researcher was employed
and the translation into English was carried out by
students at the local university.
The interviews attempted to elicit a complete picture of
how study participants viewed the experience of taking part
in GENDEP. For purposes of this paper, we will chiefly
focus on issues of informed consent in the context of
pharmacogenetic studies. The key question headings are:
For ability of articulate the concept of pharmacogenetics:
What was the purpose of GENDEP?
For eliciting appreciation of what was consented to:
What did you consent to? (the participant was shown a
copy of the consent form, which they had signed, at
this point)
For understanding blood being drawn for purposes of
genetic research:
Why do you think the researchers took the blood
samples? (again a copy of the consent form was
presented)
For absence of choice in medication prescribed (NB
this was an open-label only partially randomised trial so
it would have been inappropriate to probe for under-
standing of randomisation):
How did you feel about not having a choice in the
medication prescribed for you?
General retrospective views:
Looking back, how did you feel at the completion of
the study?
All the data were collected by researchers who had
had experience of taking anti-depressant medication as
there is evidence that respondents are more comfortable
in such a situation [11].
Data analysis
The analysis of all data was conducted in London by
service user researchers. The analysis was a thematic one[12] aided by the qualitative software NVivo2 [13]. Thus
the approach was deductive, developing themes from the
conceptual framework and interview topic guide. The soft-
ware was used to index, store and retrieve data and delin-
eate the main patterns of meaning contained within the
transcripts. Since the interview was clearly structured we
did not try to identify cross-question themes. Rather, we
shall present the results according to the main headings in
the interview. This, of course, is still an interpretive and
reflexive procedure as themes never simply ‘emerge’ from
data [12]. To preserve the anonymity of participants we
shall specify only site and not give any demographic
information.
The London researchers who were analysing the UK
and Danish data held weekly meetings with the senior
researcher (DR) for which they produced NVivo reports.
These were checked and any necessary adjustments to
coding categories and coding assignments made until
thematic saturation was reached. The researcher analys-
ing the German and Polish data produced reports for
the senior researcher by email, telephone conferences
were held and two face-to face meetings were possible,
one in Berlin and one in London. Reflexivity was an
important part of these meetings hinging particularly on
researchers’ own experiences of taking medication whilst
obviating those that were idiosyncratic.
The presentation of results includes verbatim quotations
and these were chosen to be representative of the tran-
scripts as a whole.
The study encountered some problems with ethical
procedures and this sometimes led to long intervals
between completion of the human study and the ELSI
interviews. This raised a concern that those with a very
long delay did not remember the trial very clearly simply
because it was a long time before. We therefore com-
pared three participants each in London, Mannheim and
Aarhus with short delays and three in each country with
long delays with respect to: i) their understanding of the
purpose of the trial; ii) their understanding of what they
had consented to and iii) their views on DNA testing.
We did not include participants from Poland in this
analysis as they all had long delays and, as will be seen,
their responses differed from those in other sites.Ethical considerations
The main GENDEP study received Ethical Approval from
the Institute of Psychiatry Research Committee on 2nd
June 2004, Approval Number 292/03. In Aarhus approval
was received from The Ethics Committee For Aarhus on
1st July, 2004, approval number: 20040111; in Mannheim,
from the Medical Ethics Commission at the University of
Heidelberg on 2nd June, 2004, approval number: 24/04; in
Poznan from The Karol Marcinkowski Medical University
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approval number: 1137/06.
Potential participants were sent an information sheet
prior to the interview. At the start of the interview, the
interviewer made sure that the participant understood
the information sheet and then signed consent was
taken. In terms of potential harms, it was possible that
participants might become distressed during the inter-
view and they were told they could stop at any point or
take a break. It was also made clear to potential partici-
pants that the interview study was independent of the
main pharmacogenetic trial and that no data would be
transferred between the two studies. This was to ensure
that participants felt confident in expressing their views,
knowing that the information would not be disclosed to
anyone involved in their present or future care.Results
Sample
Seventy six participants agreed to take part in the post-
study interviews. Table 1 shows the participation rates.
The median time between completion of the study and
interviews with the ELSI team was 8 months. However, in
Poznan the delay in gaining ethical approval for the ELSI
component meant that most participants had completed
the study more than one year before the interview.
A few people in our sample dropped out of the trial
part way through and these are also shown in Table 1.
We have included them in the analysis as they answered
the same questions as the completers and their answers
were no different from people who completed the whole
trial protocol. There were some specific questions about
the reasons and circumstances of discontinuing the
study but we will not include them here. The main rea-
son for dropping out was the side-effects of the medica-
tion and not process issues to do with the research.Table 1 Response rates
Contacted Interviewed Response rate
London
Completers 25 16 64%
Drop outs 7 2 29%
Mannheim
Completers 42 16 38%
Drop outs 31 3 9.7%
Aarhus
Completers 40 19 47.5%
Drop outs 0 0
Poznan
Completers 100 15 15%
Drop outs 5 5%Table 2 shows the mean age and gender distribution
across the four sites as compared to the site samples as a
whole. There were no significant differences between the
main samples and the sub-samples on either of these vari-
ables. Of course, demographic representativeness does not
mean generalisable perceptions but it does rule out demo-
graphic confounders.
Purpose of GENDEP
We considered this a very important question as without
an understanding of the purpose of the study, there can be
no informed consent. Some illustrative quotations follow:
“The purpose is to discover – that’s how I understand
the purpose I have to say – was to discover how you
respond to the medicine you take according to your
combination of genes.” (Aarhus)
“The way I got it, it was to clarify, if depressions are
genetically hereditary.” (Aarhus)
“As far as I can understand it, what they were trying
to find out was what the effect of that particular drug
was and what the side effects were and how people
reacted to it.” (London)
“From what I can remember it was about testing new
drugs. The drugs were allowed to the Polish market
by the Ministry but they required some additional
testing on volunteers. The doctor said that the study
was legal and got full support of the Ministry. That is
all I can remember.” (Poznan)
“The first aim of the study was to check my genetic
history and whether it could have effect on the history
of depression in my family.” (Poznan)Table 2 Distribution by age and gender between ELSI
sample and total sample at the 4 sites
London Mannheim Aarhus Poznan
Age
ELSI sample
Mean (SD) 45.92 (11.95) 42.47 (12.35) 39.95 (12.11) 41.89 (12.52)
N 17 17 19 19
Total sample
Mean (SD) 44.89 (12.16) 39.91 (11.25) 37.5 (10.96) 39.56 (12.28)
N 109 106 92 126
Gender
M F M F M F M F
ELSI sample 8 10 8 11 4 15 6 14
Total sample 39 70 37 33 23 50 19 68
Total 47 80 45 44 27 65 25 82
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work depending on one’s genetic disposition. So I’d
say I basically understood it.” (Mannheim)
No participant in Poznan could explain pharmacogen-
etics and in fact only a minority (19 people) could do
this. The same number believed the study to be about
testing medication. A smaller number understood that
the study had something to do with genetics but thought
it was about heritability.
Consent
At this point in the interview, the researcher showed the
participant a copy of what they had consented to (the
consent form). Many interviewees gave more than one
response to this question and, as the quotes in some il-
lustrative quotations show, often responses about risks
and consent overlap in the dialogue of the interview.
The dialogue illustrates ambivalence and this is not spe-
cific to this population but occurs in everyday discourse
[14]. However, it was clear that about half of respon-
dents were aware of risks when they signed the consent
form. This, of course, means that half were not. Some il-
lustrative quotations follow:
“Well, I knew that I consented to being included in
the study. But I cannot tell I knew what it was all
about and still don’t know.” (Poznan)
“I’ve read everything very thoroughly before I signed
anything and said “I won’t be injected with anything, I
won’t take any other drugs, only those prescribed by
Dr X [the treating neurologist].” And he [researcher]
said “Ok, ok.” (Mannheim)
“But you know I could get run over crossing the road,
you know there’s a bigger risk crossing the road than
there is something going wrong in a drugs trial. So life
is about risks, that’s not something that really bothers
me.” (London)
I: Were you told about any risks involved with taking
part in the study?
P: “No. I know that side effects can occur after any
drug but nobody told me anything special about the
drugs.” (Poznan)
I: Did anybody inform you about the risks?
P: “Yes. And that there probably would be hardly any.
That the drug has been used for years in hospitals.
That it would be pretty much the same basically if I
got one or the other.” (Mannheim)DNA/blood sampling
In this part of the interview, the interviewer once again
showed the consent form to the interviewee as an aide-
memoire. Despite the increasing concern of bioethicists,
participants in our study mostly did not object to having
blood taken. This is the one question where a substantial
number of participants could not remember the reason
for the blood being taken. Others were not concerned
about it, even if they did understand that it was to be
used to collect information about their DNA. Six re-
spondents, across all sites, voiced an initial concern
about confidentiality but these fears tended to be allayed
when the research team explained that confidentiality
was assured. Some illustrative quotations follow:
“I don't think I know what it means. “I agree that a
sample of blood can be used to make a cell line in
order to provide sufficient DNA for the genetic
analysis.” I must have agreed to it.” (London)
I: Do you recall what you consent to?
P: “That I participate in the study. And then there’s
this study and they collected some blood. That was
collected every three weeks, I believe.”
I: You do know, however, that you provided
information about your genetics by means of the blood
collection?
P: “Yes, precisely, this genetical thingy, yes, it was sent
abroad.” (Poznan)
I: Yes, well that’s good. In the next point it says: “I
allow, that DNA can be drawn, meaning genomic
material from my blood samples, and that this can be
used for genetic analysis in the GENDEP-project?”
P: “Yes, but I signed for that somewhere too.”
I: You did?
P: “Yes.”
I: Do you remember?
P: “No.”
I: You don’t remember?
P: “No.” (Aarhus)
“But I remember that it was nothing I had a problem
with. It was, just let me think for a moment. I think it
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people looked through my results, people who weren’t
the ones doing the interviews.” (Aarhus)
“I didn’t question it very critically then. But I did ask
my GP and he said those data were treated very
confidentially and wouldn’t be published, well maybe
that’s the wrong word, but that there wasn’t any
danger that the employer or health insurance got
access to the data.” (Mannheim)Lack of choice of medication
This was an open-label part-randomised trial so we can-
not determine if our participants understood the princi-
ples of randomisation. However, the literature shows
that it is choice and decision making that is focused on
by participants in trials, at least in trials of cancer treat-
ments [15]. We therefore asked our participants what
they felt about not being able to choose the anti-
depressant they were assigned. The main category of re-
sponse was that doctors always choose medication and
so it is not surprising that they did in this study too.
This was underpinned by two conceptualisations. Par-
ticipants trusted their doctors and this reference to trust
should not be underestimated as it occurred frequently
throughout the transcripts. Others were more cynical,
saying there is nothing a patient can do – that doctors
always decide. Some illustrative quotations are given. It
can be seen from the quotation from Poznan, that some
physicians were giving participants information about
the two medications and saying that they chose which
one to prescribe according to the patient’s perceived
problems. However, lack of choice was less of a problem
in this study than indicated by Ellis [1]. Nonetheless,
and somewhat tangentially, we did ask our participants
about their preferred treatment for depression and only
11 out of 76 said that this was medication alone, although
a combination of medication and talking treatments was
the most commonly given option. Some illustrative quota-
tions follow:
“Yes, you might say, that I trusted the professionalism
of it. I assumed, my subconscious mind did, actually
in the beginning I just let myself drag along, but it
had something to do with, that it was professionals in
here.” (Aarhus)
“I knew that because I asked if I might choose. I
simply got “no” for an answer but then again I’m
happy with what I’m given.”
How did you feel regarding the fact that you weren’t
allowed to choose?“Actually bad, but I though to myself the doctor won’t
tell me to take anything that’s bad for me, I can rely
on that, but I would have liked to have a choice,
though.” (Mannheim)
“After some consideration the doctor suggested which
of the drugs will be better for me. He introduced me
briefly to both of them and said that the one he
selected for me would be more suitable for me.”
(Poznan)
“That was something that was settled with a draw, as
far as I remember, meaning that it was random, so it
wasn’t really a demand I made, because I wanted to
join, it was just a crucial factor to me, deciding if I
wanted to join or not, because you can’t really meet a
demand, when it’s something that happens randomly,
and then it was kind of lucky.” (Aarhus)
Completion of GENDEP
The majority of participants in all sites said they enjoyed
participating in GENDEP. Words such as ‘sad’ or ‘disap-
pointed’ were commonly used about the trial coming to
an end. However, the reasons for enjoying the trial differed
between the sites. Over two thirds of our participants in
London, Mannheim and Aarhus mentioned the trial
researcher as the reason they felt positive about the study.
They appreciated the weekly contact and the pleasant
demeanour of the trial researcher. Even with sensitive
subjects – such as sexual side-effects of medication - they
felt comfortable.
References to the relationship with the researcher were
most marked in Mannheim. Only two people did not
mention this. Participants talked about this at great
length:
“One felt cared for, I could talk to her [the researcher]
although there were two or three others sitting there.
I didn’t have a problem talking about my problems,
whether it’s something sexual, I could just talk about
it. I just felt protected and great. And the
improvement that I had to - change your attitudes
and everything where one says “take it easy”, I’m sure
the study aimed at that. In how far the drug
influenced that I can’t tell. Some doctors also told me
I’d be taking some dextrose, well ok. Might be, but I
felt better.” (Mannheim)
This quotation is interesting as it implies that weekly
contact with the researchers was as important as medi-
cation in the relief of depression. However, this should
not be overstated. Especially in London, participants
were often vague about why they felt disappointed that
the trial had come to an end.
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study ended was quite different. There were no references
to good relations with researchers, indeed some partici-
pants said they felt like ‘guinea pigs’ and that the doctors
were not interested in them personally. The problem for
participants in Poznan who had been assigned to the new
generation drug was that they had to discontinue it at the
end of the study. This was on grounds of expense. The old
generation medication was free in that country but partici-
pants felt forced into taking it or discontinued medication
altogether.
A large majority of participants said they would take
part in another clinical study. This was the part of the
interviews where issues of ‘altruism’ were apparent. As
to recommending to someone else participating in a
trial, the majority also said they would do this although
many thought that the person should make up their own
minds in light of full information.
Memory
There were no discernible differences in understanding
of the purposes of the trial with respect to the length of
time between completion and ELSI interview. Further,
the sub-sample of transcripts mirrored the whole data
set in this. Similarly, there were no differences in appre-
ciation of harms depending on whether the delay had
been short or long between study completion and inter-
view and again the sub-sample reflected the total data set.
The sub-sample also mirrored the main sample with re-
spect to DNA profiling. Most did not recognise the clause
on the consent form but neither were they concerned
when prompted and there was no difference between
those with a short and those with a long delay between
completion of the trial and ELSI interview.
Discussion
Apart from the rather different work of Roberts [5], this
is one of the first studies to elicit the first hand accounts
of understandings of participants in a trial of a biomedical
intervention in psychiatry. Certainly it is the first to inves-
tigate this in pharmacogenetics. Although pharmacogenet-
ics is a difficult concept to grasp, it was not beyond the
understanding of some of our participants, albeit a minor-
ity. Proper informed consent means that care should al-
ways be taken to ensure that participants understand what
a trial involves so as to preserve their autonomy in coming
to a decision about whether or not they wish to take part.
This raises again the issue of informed consent and de-
cisional capacity in research studies which we touched
on in the introduction. There is a limited literature on
decision making capacity and depression. Rudnick [16]
suggests that the predominance of cognitive tests in in-
struments such as the various versions of the MCCAT
[17] underplay emotional factors which may impairdecision making in depressed patients for treatment. Elliot
[18] makes a similar argument for the capacity to partici-
pate in research. However, both these papers concern se-
verely depressed individuals and the participants in our
study were not eligible if they met diagnostic criteria for
major depression. The inclusion criteria specified ‘mild to
moderate depression’. The McArthur group itself [19] car-
ried out an empirical study with moderately depressed
women attending for outpatient psychotherapy and found
a high level of capacity when utilising the research version
of the MCCAT (MCATT-CR). Although this does not
invalidate the arguments of authors such as Rudnick or
Elliot, the overall literature suggests that decisional cap-
acity and therefore the capacity to give informed consent
is not impaired in the group who participated in GENDEP.
Therefore, their recollections and views must be taken at
face value.
In terms of our second aim, it is clear that the under-
standings of those who participated in GENDEP did not
correspond to the aims of the scientists who conducted
the study. Many thought the study was about testing
medication or heritability, that there were no risks and
were unclear about tissue sampling. There is evidence
also of the ‘therapeutic misconception’ [2,3] and the view
that participants should be able to choose the interven-
tion they receive thus indicating that randomisation re-
mains a hurdle to participation in trials [1]. These are
not new findings but this study sets them in a new con-
text and one which is likely to become more common as
complex biomedical interventions are trialled. Still less is
this a critique of GENDEP in particular but is likely to
be true of any study involving human participants in any
clinical trial. Nevertheless it is incumbent on researchers
to make every effort to ensure an adequate understanding.
If information sheets or informed consent procedures are
not adequate this is a failure of the ethical approval
system.
Multi-site studies face particular difficulties. Language is
an issue but there is also the problem that different coun-
tries and cultures will have different ethical requirements
and arrangements as well as different health service con-
figurations. The latter affect attitudes to both conducting
and participating in studies such as GENDEP.
Our participants had difficulty understanding the infor-
mation and consent sheets and this certainly is not specific
to this study. Various methods have been proposed to in-
crease comprehension [20]. One method that has not been
used, and which we would propose, is to have lay persons
involved in drawing up such documents. This has just
commenced in mental health in the UK [21]. Researchers
who have experience of the diagnosis under consideration
could also be deployed, as was done here. Further research
could also take the form of a trial of re-presenting the
information and consent sheets to randomly allocated
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understanding. This is consistent with the arguments of
Allmark and Mason [22] who used continuous consent to
parents in a trial of Total Body Hypothermia (TOBY) for
extremely premature babies.
Limitations
There was a long delay between completing GENDEP
and being interviewed about it for some participants and
this could affect their original understandings or pro-
voked revisions in the meantime. However, we found no
differences between those who responded a short time
and a longer time since completing the main study on
the main concepts of interest. Moreover, participation in
GENDEP was a very intensive procedure. There was little
evidence that participants had simply forgotten it. Partici-
pants met with researchers every week for 12 weeks for an
interview that could last for up to two hours. Follow-up
interviews were conducted six months post-study. In
addition, blood was taken every 3 weeks. Our sub-study
analysis suggests that the various understandings of the
trial and its implications for harm and tissue sampling
were not affected by the long interval between trial com-
pletion and ELSI interview. The ELSI part of the GENDEP
study was set up to be independent of the main human
study and there was no transfer of individual data between
the two investigations. Participants were assured of this.
This has the consequence that we have no information
about participants’ psychiatric condition that might have
compromised their ability to consent although we have
argued that this is unlikely in this group. In addition, con-
sent would not have been taken by the main study investi-
gators had capacity been in doubt.
Future work
A further consequence of the separation of the two in-
vestigations is that we have no information about clinical
outcomes for our participants and so cannot correlate
perceptions with benefit or harm. A major question that
arises from this research is whether the factors we have
identified make any difference to outcome. Do people
who understand what the trial is about and understand
what they have consented to achieve a better response
to the biomedical intervention? Does the social context
make a difference? There is some evidence in our study
that intense contact with another person (the researcher)
might have had an impact on the relief of depression.
Future trials might correlate interview data such as that
presented here with outcome data from biomedical in-
terventions in trials to see whether extraneous factors
might be causative in amelioration of problems.
GENDEP investigated a biomedical intervention, com-
paring two anti-depressant medications. Much emphasis
today is placed on ‘translational’ research wherebybiomarkers are identified in order to develop better
treatments. Only 11 out of 76 participants said that their
preferred treatment for depression was medication
alone, although a combination of medication and talking
treatments was the most commonly given option. So in
addition to the ethical concerns raised by this study it
has also raised a further issue about the acceptability of
the outcomes of this research. Biomedical researchers
will need to be alert to the priorities of patients as well as
researchers when embarking on translational research.
Conclusion
Participants in this study showed a poor level of informed
consent. Although this is not the first time this argument
has been made, it is in the case of a pharmacogenetic trial.
Further work should investigate the associations between
extraneous factors such as information and social support
on beneficial or untoward outcomes of antidepressant
treatment.
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